PRIORITY ONE SERVICES, INC. - INDEFINITE DELIVERY, INDEFINITE QUANTITY (IDIQ) CONTRACT TO PROVIDE ANIMAL HUSBANDRY SERVICES AND VIVARIUM MANAGEMENT FOR CBER/CDER AND CDRH WITH A 5 YEAR ORDERING PERIOD
Key Details
Description
INDEFINITE DELIVERY, INDEFINITE QUANTITY (IDIQ) CONTRACT TO PROVIDE ANIMAL HUSBANDRY SERVICES AND VIVARIUM MANAGEMENT FOR CBER/CDER AND CDRH WITH A 5 YEAR ORDERING PERIOD
Context & Analysis
On Nov 18, 2025, Department of Health and Human Services obligated $25,000 to PRIORITY ONE SERVICES, INC. for indefinite delivery, indefinite quantity (idiq) contract to provide animal husbandry services and vivarium management for cber/cder and cdrh with a 5 year ordering period. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a order dependent (idv allows pricing arrangement to be determined separately for each order) contract. Competition extent: full and open competition after exclusion of sources with 5 offers received. The procurement used a SMALL BUSINESS SET ASIDE - TOTAL set-aside. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Related Opportunities
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.